Evolus Inc logo

Evolus Inc

NAS:EOLS (USA)  
$ 11.43 -0.03 (-0.26%) 10:08 PM EST
At Loss
Market Cap:
$ 702.92M
Enterprise V:
$ 768.47M
Volume:
248.66K
Avg Vol (2M):
598.84K
Also Trade In:
Volume:
248.66K
At Loss
Avg Vol (2M):
598.84K

Business Description

Description
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Name Current Vs Industry Vs History
Cash-To-Debt 0.5
Equity-to-Asset -0.11
Debt-to-Equity -6.12
Debt-to-EBITDA -3.03
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.48
Distress
Grey
Safe
Beneish M-Score -2.93
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 19.77
9-Day RSI 19.24
14-Day RSI 23.58
6-1 Month Momentum % 78.25
12-1 Month Momentum % 64.68

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.33
Quick Ratio 2.1
Cash Ratio 1.3
Days Inventory 107.62
Days Sales Outstanding 49.09
Days Payable 50.98

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.7
Shareholder Yield % -3.58

Financials (Next Earnings Date:2024-05-09 Est.)

EOLS's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:EOLS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Evolus Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 202.085
EPS (TTM) ($) -1.08
Beta 1.12
Volatility % 59.81
14-Day RSI 23.58
14-Day ATR ($) 0.432611
20-Day SMA ($) 12.54825
12-1 Month Momentum % 64.68
52-Week Range ($) 7.07 - 15.4325
Shares Outstanding (Mil) 61.5

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Evolus Inc Filings

Filing Date Document Date Form
No Filing Data

Evolus Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Evolus Inc Frequently Asked Questions

What is Evolus Inc(EOLS)'s stock price today?
The current price of EOLS is $11.43. The 52 week high of EOLS is $15.43 and 52 week low is $7.07.
When is next earnings date of Evolus Inc(EOLS)?
The next earnings date of Evolus Inc(EOLS) is 2024-05-09 Est..
Does Evolus Inc(EOLS) pay dividends? If so, how much?
Evolus Inc(EOLS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1